Pegcetacoplan

Generic Name
Pegcetacoplan
Brand Names
Empaveli, Syfovre, Aspaveli
Drug Type
Biotech
Chemical Formula
-
CAS Number
2019171-69-6
Unique Ingredient Identifier
TO3JYR3BOU
Background

Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Prior to its FDA approval, patients with PNH were typically treated with the C5 inhibiting monoclonal antibody eculizumab. Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat suscepti...

Indication

Pegcetacoplan is indicated to treat adults with paroxysmal nocturnal hemoglobinuria (PNH). It is also indicated to treat geographic atrophy (GA) secondary to age-related macular degeneration.

Associated Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration, Paroxysmal Nocturnal Haemoglobinuria (PNH)
Associated Therapies
-
Clinical Trials
Related News

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

First Posted Date
2024-12-09
Last Posted Date
2024-12-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
180
Registration Number
NCT06722157
Locations
🇺🇸

Associated Retina Consultants, Gilbert, Arizona, United States

🇺🇸

Associated Retina Consultants, Ltd., Phoenix, Arizona, United States

🇺🇸

Phoenix Retina Associates, Phoenix, Arizona, United States

and more 38 locations

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Recruiting
Conditions
Geographic Atrophy
Interventions
Drug: Pegcetacoplan
First Posted Date
2023-12-08
Last Posted Date
2024-05-31
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
300
Registration Number
NCT06161584
Locations
🇺🇸

Retinal Consultants Medical Group Inc (01-008), Modesto, California, United States

🇺🇸

Retina-Vitreous Associates Medical Group (01-020), Beverly Hills, California, United States

🇺🇸

Long Island Vitreoretinal Consultants (01-013), Westbury, New York, United States

and more 28 locations

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

First Posted Date
2023-04-12
Last Posted Date
2024-03-12
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
100
Registration Number
NCT05809531
Locations
🇧🇷

Santa Casa de Misericordia de Belo Horizonte (55017), Belo Horizonte, Minas Gerais, Brazil

🇨🇭

CHUV Lausanne (41002), Lausanne, Switzerland

🇧🇷

HC UNESP Botucatu (55010), Botucatu, Brazil

and more 23 locations

A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

First Posted Date
2023-03-20
Last Posted Date
2024-08-06
Lead Sponsor
Swedish Orphan Biovitrum
Target Recruit Count
200
Registration Number
NCT05776472
Locations
🇪🇸

Hospital Lucus Augusti, Lugo, Spain

Evaluate the PK Efficacy Safety and Tolerability of Pegcetacoplan in Patients With Thrombotic Microangiopathy

First Posted Date
2021-12-08
Last Posted Date
2024-12-19
Lead Sponsor
Swedish Orphan Biovitrum
Target Recruit Count
12
Registration Number
NCT05148299
Locations
🇬🇷

University General Hospital "Attikon", Athens, Chaidari, Greece

🇫🇷

CHU de Saint-Etienne, Saint-Priest-en-Jarez, France

🇬🇷

General Hospital of Thessaloniki "G. Papanikolaou", Hematology Department - BMT Unit, Thessaloníki, Greece

and more 11 locations

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

Phase 3
Suspended
Conditions
Cold Agglutinin Disease
Interventions
Drug: Pegcetacoplan
First Posted Date
2021-10-27
Last Posted Date
2024-04-11
Lead Sponsor
Swedish Orphan Biovitrum
Target Recruit Count
57
Registration Number
NCT05096403
Locations
🇬🇪

Ltd M. Zodelava Hematology Centre, Tbilisi, Georgia

🇬🇧

Churchill Hospital, Oxford, United Kingdom

🇧🇪

CHU de Liège, Liège, Belgium

and more 41 locations

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

First Posted Date
2021-10-05
Last Posted Date
2024-07-26
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
90
Registration Number
NCT05067127
Locations
🇳🇱

University Medical Center Groningen, Groningen, Netherlands

🇳🇱

Emma Kinderziekenhuis, Amsterdam UMC, Amsterdam, Netherlands

🇳🇱

Radboud University Medical Center, Nijmegen, Netherlands

and more 120 locations

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

First Posted Date
2021-06-09
Last Posted Date
2024-06-20
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
60
Registration Number
NCT04919629
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

First Posted Date
2021-05-26
Last Posted Date
2022-07-20
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
12
Registration Number
NCT04901936
Locations
🇹🇭

Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand

🇨🇿

Motol University Hospital, Prague, Czechia

🇺🇸

Children's Hospital of Atlanta, Atlanta, Georgia, United States

and more 7 locations

C3G/Primary IC-MPGN EAP

First Posted Date
2021-01-28
Last Posted Date
2024-07-26
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Registration Number
NCT04729062
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy